### UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

Docket No. 01290/1

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Total Pages in this Submission

2 U.S. P

#### TO THE COMMISSIONER FOR PATENTS

Mail Stop Patent Application P.O. Box 1450 Alexandria, VA 22313-1450

<b>~</b>		Alexandria, VA 22515-1450											
Transmitted herewith for filing under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new utility patent application for an invention entitled:													
ANTISENSE MODULATION OF FARNESOID X RECEPTOR EXPRESSION													
and invent	ted by:												
Chri	Christopher D. Kane												
If a CONTINUATION APPLICATION, check appropriate box and supply the requisite information:													
☐ Con	tinuati	ion Divisional Continuation-in-part (CIP) of prior application No.:											
Which is	a:												
☐ Con	tinuati	ion Divisional Continuation-in-part (CIP) of prior application No.:											
Which is	a:												
☐ Con	tinuati	ion Divisional Continuation-in-part (CIP) of prior application No.:											
Enclosed are:													
		Application Elements											
1. 🗵 Filing fee as calculated and transmitted as described below													
2. 🛚	l Spe	cification having 148											
a	. 🛛	Descriptive Title of the Invention											
b	. 🛛	Cross References to Related Applications (if applicable)											
С	. 🗆	Statement Regarding Federally-sponsored Research/Development (if applicable)											
d. 🗵 Reference to Sequence Listing, a Table, or a Computer Program Listing Appendix													
e	. 🛛	Background of the Invention											
f	. 🛛	Brief Summary of the Invention											
 g	. 🛛	Brief Description of the Drawings (if filed)											
· h	. 🛛	Detailed Description											
i	. 🛛	Claim(s) as Classified Below											
· j	. 🗵	Abstract of the Disclosure											
•													

## UTILITY PATENT APPLICATION TRANSMITTAL (Larg Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. 01290/1

Total Pages in this Submission

Application El ments (Continued)													
3.	X	Drawing(s) (when necessary as prescribed by 35 USC 113)											
	a.	▼ Formal Number of Sheets 2											
	b.	☐ Informal Number of Sheets											
4.		Oath or Declaration											
	a.	☐ Newly executed (original or copy) ☐ Unexecuted											
	b.	☐ Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional application only)											
	c.	☐ With Power of Attorney ☐ Without Power of Attorney											
	d.	DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. 1.63(d)(2) and 1.33(b).											
5.		Incorporation By Reference (usable if Box 4b is checked) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.											
6.		CD ROM or CD-R in duplicate, large table or Computer Program (Appendix)											
7.		Application Data Sheet (See 37 CFR 1.76)											
8.	X	Nucleotide and/or Amino Acid Sequence Submission (if applicable, all must be included)											
	a.	Computer Readable Form (CRF)											
	b.	Specification Sequence Listing on:											
		i. D CD-ROM or CD-R (2 copies); or											
		ii. 🛚 Paper											
	C.	Statement(s) Verifying Identical Paper and Computer Readable Copy											
		Accompanying Application Parts											
9.		Assignment Papers (cover sheet & document(s))											
10.		37 CFR 3.73(B) Statement (when there is an assignee)											
11.		English Translation Document (if applicable)											
12.		Information Disclosure Statement/PTO-1449   Copies of IDS Citations											
13.		Preliminary Amendment											
14.	X	Return Receipt Postcard (MPEP 503) (Should be specifically itemized)											
15.		Certified Copy of Priority Document(s) (if foreign priority is claimed)											
16.	X	Certificate of Mailing											
		☐ First Class ☒ Express Mail (Specify Label No.):											

# UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. 01290/1

Total Pages in this Submission

	Accompanying Application Parts (Continued)								
17.		Additional Enclosures (please identify below):							
		Request That Application Not Be Published Pursuant To 35 U.S.C. 122(b)(2)							
18.		Pursuant to 35 U.S.C. 122(b)(2), Applicant hereby requests that this patent application not be published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in this application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication of applications 18 months after filing of the application.							
	Warning								
		An applicant who makes a request not to publish, but who subsequently files in a foreign country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), must notify the Director of such filing not later than 45 days after the date of the filing of such foreign or international application. A failure of the applicant to provide such notice within the prescribed period shall result in the application being regarded as abandoned, unless it is shown to the satisfaction of the Director that the delay in submitting the notice was unintentional.							

### UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. 01290/1

Total Pages in this Submission

Fee	Cald	ulatio	n and	Trans	mittal

#### **CLAIMS AS FILED** For #Filed #Allowed #Extra Rate Fee **Total Claims** \$144.00 28 - 20 = 8 \$18.00 X Indep. Claims 1 - 3 = 0 \$0.00 \$84.00 X Multiple Dependent Claims (check if applicable) \$280.00 **BASIC FEE** \$750.00 OTHER FEE (specify purpose) \$0.00 TOTAL FILING FEE \$1,174.00 A check in the amount of to cover the filing fee is enclosed. The Director is hereby authorized to charge and credit Deposit Account No. 19-1025 as described below. ☑ Charge the amount of \$1,174.00 as filing fee. ☑ Credit any overpayment. ☑ Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17. ☐ Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance, pursuant to 37 C.F.R. 1.311(b). Signature Dated: September 25, 2003 S. Christopher Bauer 42,305 cc:

#### CERTIFICATE OF MAILING BY FIRST-CLASS MAIL (37 CFR 1.8)

Serial No: Not Assigned

Filing Date: September 25, 3003 Group Art Unit: Not Assigned

Docket No: 01290/1

Invention: ANTISENSE MODULATION OF FARNESOID X RECEPTOR EXPRESSION

Date of Deposit: September 25, 2003

I hereby certify that these papers or fee is being deposited with the United States Post Office to Addressee service under 37 CFR 1.10 & 1.8 on the date indicated above and is addressed to Mail Stop New Application, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450:

Utility Patent Application Transmittal Letter Application (1-148 pages)
Abstract
Figure 1 (2 pages)
Paper Copy of Sequence Listing (433 pages)
CRF of Sequence Listing
Statement under 37 CFR § 1.821(f)
Return Postcard

Linda Haley

(Typed or printed name of person mailing paper or fee)

Signature of person mailing paper or fee)

EXPRESS MAIL LABEL NO: EV 325912001 US